Copyright
©The Author(s) 2017.
World J Gastroenterol. Feb 28, 2017; 23(8): 1406-1411
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1406
Published online Feb 28, 2017. doi: 10.3748/wjg.v23.i8.1406
Table 1 Summary of patient baseline characteristics
| Overall cohort (n = 42) | TOMOX (n = 18) | FOLFOX (n = 24) | P value | |
| Gender | 0.700 | |||
| Male | 29 | 13 | 16 | |
| Female | 13 | 5 | 8 | |
| Age at first TACE (yr) | 59 ± 10.7 | 60 ± 9.1 | 58 ± 11.8 | 0.473 |
| Primary tumor site | 0.601 | |||
| Right hemicolon | 10 | 5 | 5 | |
| Left hemicolon | 32 | 19 | 13 | |
| Time to liver metastasis | 0.508 | |||
| Synchronous | 28 | 11 | 17 | |
| Metachronous | 14 | 7 | 7 | |
| Primary tumor grade | 0.639 | |||
| Poor | 6 | 3 | 3 | |
| Well to moderate | 36 | 15 | 21 | |
| Genetic condition | 0.459 | |||
| KRAS mutation | 8 | 5 | 3 | |
| KRAS wild type | 21 | 8 | 13 | |
| Unknown | 13 | 5 | 8 | |
| Extrahepatic metastasis | 0.927 | |||
| Present | 27 | 12 | 15 | |
| Absent | 15 | 6 | 9 | |
| Combined with other local treatments | 0.209 | |||
| Yes | 10 | 6 | 4 | |
| No | 32 | 12 | 20 |
Table 2 Response evaluation n (%)
| Response | Treatment group | P value | |
| FOLFOX (n = 24) | TOMOX (n = 18) | ||
| Partial response | 7 (29.2) | 2 (11.1) | 0.158 |
| Stable disease | 14 (58.3) | 11 (61.1) | 0.856 |
| Progressive disease | 3 (12.5) | 5 (27.8) | 0.734 |
Table 3 Predictors of overall survival
| Factor | Univariate analysis | ||
| HR | 95%CI | P value | |
| TOMOX/FOLFOX | 0.877 | 0.410-1.876 | 0.736 |
| Male sex | 0.915 | 0.411-2.035 | 0.827 |
| Age (> 60/60 yr) | 0.758 | 0.353-1.627 | 0.477 |
| Histology (poor/well and moderate) | 1.768 | 0.686-4.554 | 0.238 |
| Primary tumor site (left/right hemicolon) | 0.715 | 0.285-1.797 | 0.476 |
| Serum CA19-9 (high/normal) | 1.725 | 0.803-3.706 | 0.162 |
| Serum CA72-4 (high/normal) | 1.325 | 0.536-3.278 | 0.542 |
| Serum CEA (high/normal) | 1.339 | 0.463-3.873 | 0.590 |
| Extrahepatic metastasis (present/absent) | 1.220 | 0.550-2.706 | 0.624 |
| Time to liver metastasis (synchronous/metachronous) | 1.281 | 0.560-2.932 | 0.558 |
| Response to TACE | 0.047 | ||
| PD | 1.000 | 1.000 | |
| SD | 0.275 | 0.081-0.931 | |
| PR | 0.272 | 0.095-0.783 | |
Table 4 Observed toxicity according to common terminology criteria for adverse events grading n (%)
| Adverse event | TOMOX (n = 18) | FOLFOX (n = 24) | P value | ||
| All grade | Severe | All grade | Severe | ||
| Hematological | |||||
| Anemia | 7 (39) | 11 (46) | 0.212 | ||
| Leucopenia | 3 (16) | 12 (50) | 1 (4) | 0.026 | |
| Neutropenia | 1 (5) | 6 (25) | 1 (4) | 0.094 | |
| Thrombocytopenia | 8 (44) | 13 (54) | 3 (12) | 0.533 | |
| Nonhematological | |||||
| Elevation of liver enzymes | 18 (100) | 9 (50) | 19 (79) | 7 (29) | 0.039 |
| Elevation of bilirubin | 17 (94) | 3 (17) | 23 (95) | 4 (17) | 0.834 |
| Nausea/vomiting | 14 (78) | 17 (71) | 0.839 | ||
| Asthenia | 13 (72) | 12 (50) | 0.414 | ||
| Neuropathy | 5 (28) | 7 (29) | 1 (4) | 0.921 | |
| Pain | 14 (78) | 7 (39) | 19 (79) | 13 (54) | 0.914 |
| Fever | 6 (33) | 11 (46) | 0.558 | ||
- Citation: Guo JH, Zhang HY, Gao S, Zhang PJ, Li XT, Chen H, Wang XD, Zhu X. Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. World J Gastroenterol 2017; 23(8): 1406-1411
- URL: https://www.wjgnet.com/1007-9327/full/v23/i8/1406.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i8.1406
